NCT04468334已完成不适用
Non-randomized, Multicenter Expanded Use Evaluation of the LARIAT® Suture Delivery Device (Appendix 16 to Ongoing Investigation)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 82
- 试验地点
- 25
- 主要终点
- Freedom from episodes of atrial fibrillation > 30 seconds at 12 months post index pulmonary vein isolation
研究概览
简要总结
aMAZE CAP is an extension to the current aMAZE Trial investigation (IDEG150107/NCT02517397/Protocol Appendix 16) in the form of a nested, non-randomized registry, to allow ongoing treatment of subjects and the collection of additional safety and effectiveness data at existing aMAZE investigational sites.
详细描述
For consistency, aMAZE CAP primary and secondary safety and efficacy endpoints, eligibility criteria and follow up visit assessments remain unchanged from the current aMAZE Trial investigation (NCT02517397).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented diagnosis of symptomatic continuous persistent or longstanding persistent non-valvular atrial fibrillation
- •Failed at least one Class I or III Antiarrythmic drug (AAD) and therefore, eligible and intended for standard of care catheter ablation;
- •Life expectancy ≥ 1 year;
- •Willing and able to return to and comply with scheduled follow-up visits and tests; and
- •Willing and able to provide written informed consent
排除标准
- •Prior procedure involving opening of the pericardium or entering the pericardial space (e.g., coronary artery bypass graft, heart transplantation, valve surgery) where adhesions are suspected;
- •Any prior epicardial ablation or any type of left-sided atrial ablation procedure;
- •LA diameter > 6 cm as measured by computerized tomography and confirmed by the imaging core laboratory;
- •Documented embolic stroke, transient ischemic attach or suspected neurologic event within 3 months prior to the planned study intervention;
- •Currently exhibits New York Heart Association Class IV heart failure symptoms;
- •Documented history of right heart failure specifically when right ventricle exceeds the left ventricular size;
- •Documented history of myocardial infarction (MI) within 3 months prior to the planned study intervention;
- •Documented history of unstable angina within 3 months prior to the planned study intervention;
- •Documented history of cardiogenic shock, hemodynamic instability or any medical condition in which intra-aortic balloon pump (IABP) therapy is clinically indicated within 3 months prior to the planned study intervention;
- •Documented symptomatic carotid disease, defined as > 70% stenosis or > 50% stenosis with symptoms;
- •Diagnosed active local or systemic infection, septicemia or fever of unknown origin at tme of baseline screening;
- •Chronic renal insufficiency defined as eGFR < 30 mL/min/1.73m2 within 3 months prior to planned study intervention;
- •End Stage Renal Disease (ESRD) or documented history of renal replacement / dialysis;
- •Current documented history of clinically significant liver disease which predisposes the subject to significant bleeding risk (clinically defined by the treating physician);
- •Any history of thoracic radiation with the exception of localized radiation treatment for breast cancer;
- •Current documented use of long-term treatment with oral corticoid steroids, not including use of inhaled steroids for respiratory diseases;
- •Active pericarditis;
- •Active endocarditis;
- •Any documented history or autoimmune disease associated with pericarditis;
- •Evidence of Pectus Excavatum (documented and clinically defined by the treating physician);
- •Untreated severe scoliosis (documented and clinically defined by treating physician);
- •Documented Left Ventricular Ejection Fraction (LVEF) < 30% within 30 days prior to planned intervention;
- •Documented presence of implanted congenital defect closure devices, (e.g., atrial septal defect, patent foramen ovale or ventricular septal defect device);
- •Previously attempted occlusion of the left atrial appendage (by any surgical or percutaneous method);
- •Inability, or unwillingness or contraindication to undergo TEE or CTA imaging or 24-hour Holter monitoring;
- •Body Mass Index (BMI) > 40;
- •Evidence of active Graves disease;
- •Current untreated hypothyroidism;
- •Any contraindication to suture, endovascular device, or other minimally invasive techniques including percutaneous, transseptal, and/or sub-xiphoid access;
- •Subject is pregnant or plans / desires to get pregnant within next 12 months;
- •Current enrollment in an investigation or study of an investigational device or investigational drug that would interfere with this study and the required follow up;
- •Mental impairment or other psychiatric conditions which may not allow patient to understand the nature, significance and scope of the study;
- •Any other criteria, medical illness or comorbidity which would make the subject unsuitable to participate in this study as determined by the clinical site Primary Investigator;
- •Additional Exclusion Criteria: Based on Screening / Pre-procedure Imaging
- •Subjects will also be excluded if they meet any of the following:
- •Based on screening computed tomography angiography performed within 90 days prior to study intervention as confirmed by the core lab:
- •Left atrial appendage morphology: Superior-posterior oriented left atrial appendage (i.e. superior C shape), that has Left atrial appendage distal apex extending posterior to the ostium of the appendage.
- •Left atrial appendage positioned behind the pulmonary artery; or All other left atrial morphology: Left atrial appendage LARIAT approach width > 50 mm.
- •Based on a peri-procedural imaging (transesophageal echocardiography) at time of LARIAT or catheter ablation) and confirmed by institution's designated LARIAT echocardiographer:
- •Intracardiac thrombus; or Significant mitral valve stenosis (i.e., mitral valve stenosis < 1.5cm2)
- •NOTE: It is anticipated that a majority of subjects enrolled in the aMAZE CAP Trial will be elderly US Medicare beneficiaries. Therefore, the results from the aMAZE CAP Trial are expected to be generalizable to the Medicare population
研究组 & 干预措施
LARIAT + PVI Treatment Group
Experimental
Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
Subgroup 1: Radiofrequency (RF) PVI catheter ablation treatment (n<65) Subgroup 2: Cryoballoon PVI catheter ablation treatment (n<20)
干预措施: LARIAT + PVI (Device)
结局指标
主要结局
Freedom from episodes of atrial fibrillation > 30 seconds at 12 months post index pulmonary vein isolation
时间窗: 12 months following Pulmonary Vein Isolation catheter ablation procedure
Measured by 24-hour Holter Monitoring
次要结局
- Composite endpoint of stroke of any cause and systemic embolism as adjudicated by the clinical events committee(12 months following index pulmonary vein isolation)
- Freedom from any atrial fibrillation/atrial tachycardia/atrial flutter recurrence defined as any episode > 30 seconds with or without AAD(Following the 90 day blanking period through 12 months post-index pulmonary vein isolation)
研究者
研究点 (25)
Loading locations...
相似试验
进行中（未招募）
3 期
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisMembranoproliferative GlomerulonephritisC3 GlomerulopathyDDDImmune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Complement 3 GlomerulopathyMembranoproliferative Glomerulonephritis (MPGN)IC-MPGNC3 GlomerulonephritisComplement 3 GlomerulonephritisDense Deposit DiseaseC3GComplement 3 Glomerulopathy (C3G)NCT05809531Apellis Pharmaceuticals, Inc.100
进行中（未招募）
3 期
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)NeoplasmsNCT05112965Hoffmann-La Roche49
已完成
3 期
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia AreataAlopecia AreataNCT05255237Suzhou Zelgen Biopharmaceuticals Co.,Ltd315
已完成
3 期
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisMultiple SclerosisNCT03232073Actelion877
终止
2 期
Guadecitabine Extension StudyMyeloid Dysplastic SyndromeAcute Myeloid LeukemiaNCT03603964Astex Pharmaceuticals, Inc.35